Market closed
Y-mAbs/$YMAB
Y-mAbs shares are trading higher after DANYELZA was added to NCCN guidelines for high-risk neuroblastoma treatment.
23 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
$YMAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
104
ISIN
US9842411095
Website
Y-mAbs Metrics
BasicAdvanced
$183M
-
-$0.67
0.65
-
Price and volume
Market cap
$183M
Beta
0.65
52-week high
$15.70
52-week low
$3.76
Average daily volume
249K
Financial strength
Current ratio
4.157
Quick ratio
3.668
Long term debt to equity
0.207
Total debt to equity
0.891
Management effectiveness
Return on assets (TTM)
-12.67%
Return on equity (TTM)
-30.74%
Valuation
Price to revenue (TTM)
2.042
Price to book
1.98
Price to tangible book (TTM)
2.03
Price to free cash flow (TTM)
-11.397
Growth
Revenue change (TTM)
3.38%
Earnings per share change (TTM)
36.47%
3-year revenue growth (CAGR)
35.95%
3-year earnings per share growth (CAGR)
-19.41%
What the Analysts think about Y-mAbs
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.
Y-mAbs Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Y-mAbs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Y-mAbs News
AllArticlesVideos
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewsWire·3 days ago
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewsWire·4 days ago
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $183M as of May 10, 2025.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of May 10, 2025.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.